PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma
Background: Neuroendocrine carcinoma of the cervix (NECC) is more prone to lymphatic infiltration, lymph node involvement, local recurrence, and distant metastasis. Using CCRT with or without adjuvant chemotherapy as the standard treatment for locally advanced NECCs and CCRT for patients with early lesions confined to the cervix. However, the prognosis of NECC patients treated with definitive radiotherapy (RT) is unknown. Immune checkpoint inhibitors are a promising therapeutic strategy for locally advanced cervical cancer. Some reports suggest that the expression of PD-L1 in solid tumors correlates with prognosis.
Aim: This study investigates prognostic factors for survival in patients with neuroendocrine cervical carcinoma (NECC) treated with definitive radiotherapy (RT) and the relationship between PD-L1 expression and prognosis in these patients.
Methods: This retrospective study included 66 patients with histologically confirmed NECC who received RT with or without chemotherapy. From January 2015 to December 2020, patients received routine extended-field irradiation (EFI), and PD-L1 expression was assessed by immunohistochemistry. The most commonly used chemotherapy agents were etoposide-platinum and paclitaxel-platinum.
Results: PD-L1 expression was positive in 17 of 45 (37.8%) patients. There were 52 cases of pure NECC and 14 cases of mixed carcinoma. Sixty stage IB-III patients received definitive RT. The 3- and 5-year progression-free survival (PFS) was 39.8% and 34.1%, and 3- and 5-year overall survival (OS) was 48.0% and 40.2%, respectively. There was no significant difference in 3 and 5-year PFS and 3 and 5-year OS between patients with pure and mixed carcinoma. Positive PD-L1 expression was associated with higher 3-year PFS in patients with mixed histology. Univariate analysis showed that LNM and FIGO stages predicted 3-and 5-year PFS in patients who received definitive RT. The median OS in patients receiving less than four cycles and at least four cycles of chemotherapy (CT) was 26.0 and 44.0 months, respectively (P=0.038); moreover, 3- and 5-year PFS was 34.1% and 25.7% in the former and 46.4% and 40.4% in the latter. There were no significant differences in OS and PFS between pelvic irradiation and prophylactic EFI in patients treated with definitive RT. There were no significant differences in para-aortic failure rate after concurrent chemoradiotherapy between patients who underwent pelvic irradiation or prophylactic EFI (p=0.147).
Conclusion: In patients with mixed NECC, positive PD-L1 expression is correlated with higher 3-year PFS. Chemoradiotherapy was effective for NECCs. The LNM and stage predicted PFS. Four or more cycles of chemotherapy improve prognosis. Prophylactic EFI did not significantly improve PFS and OS.
Relevance for patients: This study is relevant to patients as it confirms that chemoradiotherapy is effective for both early and locally advanced NECC, and that four or more cycles of chemotherapy improved prognosis. The regimen should be carefully evaluated to ensure that patients receive the most effective radiation therapy for the prophylactic of para-aortic lymph node metastasis. Potential risk factors for recurrence of radical radiotherapy should be fully understood to minimize these risks. This study observed that PD-L1 expression positive in patients with mixed NECC types is correlated with higher 3-year PFS.
[1] Gadducci A, Carinelli S, Aletti G. Neuroendrocrine Tumors of the Uterine Cervix: A Therapeutic Challenge for Gynecologic Oncologists. Gynecol Oncol 2017;144:637-46.
[2] Burzawa J, Gonzales N, Frumovitz M. Challenges in the Diagnosis and Management of Cervical Neuroendocrine Carcinoma. Expert Rev Anticancer Ther 2015;15:805-10.
[3] Salvo G, Martin AG, Gonzales NR, Frumovitz M. Updates and Management Algorithm for Neuroendocrine Tumors of the Uterine Cervix. Int J Gynecol Cancer 2019;29:986-95.
[4] Kitajima K, Kihara T, Kawanaka Y, Kido A, Yoshida K, Mizumoto Y, et al. Neuroendocrine Carcinoma of Uterine Cervix Findings Shown by MRI for Staging and Survival Analysis-Japan Multicenter Study. Oncotarget 2020;11:3675-86.
[5] Atienza-Amores M, Guerini-Rocco E, Soslow RA, Park KJ, Weigelt B. Small Cell Carcinoma of the Gynecologic Tract: A Multifaceted Spectrum of Lesions. Gynecol Oncol 2014;134:410-8.
[6] Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine Tumors of the Gynecologic Tract: ASociety of Gynecologic Oncology (SGO) Clinical Document. Gynecol Oncol 2011;122:190-8.
[7] Zhang Y, Li L, Wang Z, Huang Y, Luo S, Peng Y, et al. Preferred Method of Therapy for Patients with Early-stage High-grade Neuroendocrine Carcinoma of the Cervix. Am J Cancer Res 2021;11:4595-606.
[8] Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical Cancer. Lancet 2019;393:169-82.
[9] De Felice F, Marchetti C, Palaia I, Ostuni R, Muzii L, Tombolini V, et al. Immune Check-point in Cervical Cancer. Crit Rev Oncol Hematol 2018;129:40-3.
[10] Towner M, Novak K, Chae YK, Matei D. Ipilimumab and Nivolumab for Recurrent Neuroendocrine Cervical Carcinoma. Gynecol Oncol Rep 2022;42:101039.
[11] Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing Tumorinfiltrating T Cells are a Favorable Prognostic Biomarker in HPV-associated Head and Neck Cancer. Cancer Res 2013;73:128-38.
[12] Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical Impact of Programmed Cell Death Ligand 1 Expression in Colorectal Cancer. Eur J Cancer 2013;49:2233-42.
[13] Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is Expressed by Tumorinfiltrating Immune Cells and is Associated with Poor Outcome for Patients with Renal Cell Carcinoma. Clin Cancer Res 2007;13:1757-61.
[14] Loharamtaweethong K, Puripat N, Praditphol N, Thammasiri J, Tangitgamol S. PD-L1 Protein Expression and Copy Number Gains in HIV-positive Locally Advanced Cervical Cancer. Ther Adv Med Oncol 2020;12:1-15.
[15] Alejo M, Alemany L, Clavero O, Quiros B, Vighi S, Seoud M, et al. Contribution of Human Papillomavirus in Neuroendocrine Tumors from a Series of 10,575 Invasive Cervical Cancer Cases. Papillomavirus Res 2018;5:134-42.
[16] Morgan S, Slodkowska E, Parra-Herran C, Mirkovic J. PD-L1, RB1 and Mismatch Repair Protein Immunohistochemical Expression in Neuroendocrine Carcinoma, Small Cell Type, of the Uterine Cervix. Histopathology 2019;74:997-1004.
[17] Ji X, Sui L, Song K, Lv T, Zhao H, Yao Q. PD-L1, PARP1, and MMRS as Potential Therapeutic Biomarkers for Neuroendocrine Cervical Cancer. Cancer Med 2021;10:4743-51.
[18] Chen L, Yang F, Feng T, Wu S, Li K, Pang J, et al. PD-L1, Mismatch Repair Protein, and NTRK Immunohistochemical Expression in Cervical Small Cell Neuroendocrine Carcinoma. Front Oncol 2021;11:752453.
[19] Sun X, Liu L, Wan T, Huang Q, Chen J, Luo R, et al. The Prognostic Impact of the Immune Microenvironment in Small-cell Neuroendocrine Carcinoma of the Uterine Cervix: PD-l1 and Immune Cell Subtypes. Cancer Cell Int 2022;22:348.
[20] Carroll MR, Ramalingam P, Salvo G, Fujimoto, Soto LMS, Phoolcharoen N, et al. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int J Gynecol Cance 2020;30:1303-7.
[21] Cimic A, Vranic S, Arguello D, Contreras E, Gatalica Z, Swensen J. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix. Appl Immunohistochem Mol Morphol 2021;29:299-304.
[22] Gu X, Dong M, Liu Z, Mi Y, Yang J, Zhang Z, et al. Elevated PD-L1 Expression Predicts Poor Survival Outcomes in Patients with Cervical Cancer. Cancer Cell Int 2019;19:146.
[23] Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, et al. Expression of PD-L1 and Presence of CD8-positive T Cells in Pre-treatment Specimens of Locally Advanced Cervical Cancer. Mod Pathol 2017;30:577-86.
[24] Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, et alThe impact of PD-L1 expression in patients with metastatic GEP-NETs. J Cancer 2016;7:484–9.
[25] Pei X, Xiang L, Chen W, Jiang W, Yin L, Shen X, et al. The Next Generation Sequencing of Cancer-related Genes in Small Cell Neuroendocrine Carcinoma of the Cervix. Gynecol Oncol 2021;161:779-86.
[26] Hou WH, Schultheiss TE, Wong JY, Wakabayashi MT, Chen YJ. Surgery Versus Radiation Treatment for High-grade Neuroendocrine Cancer of Uterine Cervix: A Surveillance Epidemiology and End Results Database Analysis. Int J Gynecol Cancer 2018;28:188-93.
[27] Winer I, Kim C, Gehrig P. Neuroendocrine Tumors of the Gynecologic Tract Update. Gynecol Oncol 2021;162:210-9.
[28] Chen J, Sun Y, Chen L, Zang L, Lin C, Lu Y, et al. Prognostic Factors and Treatment of Neuroendocrine Tumors of the Uterine Cervix Based on the FIGO 2018 Staging System: A Single-institution Study of 172 Patients. PeerJ 2021;9:e11563.
[29] Ruiz MP, Dziadek OL, Algren SD. Nonsurgical Management of Neuroendocrine Cancer of the Cervix: Brief Report. Int J Gynecol Cancer 2016;26:1290-2.
[30] Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, et al. Small-cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-modality Regimen of Involved-field Irradiation and Platinum-based Combination Chemotherapy. J Clin Oncol 2003;21:3495-501.
[31] Bajaj A, Gopalakrishnan M, Harkenrider MM, Lurain JR, Small W Jr. Advanced Small Cell Carcinoma of the Cervixsuccessful Treatment with Concurrent Etoposide and Cisplatin Chemotherapy and Extended Field Radiation: A Case Report and Discussion. Gynecol Oncol Rep 2018;23:4-6.
[32] Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, Chen LM, et al. Small Cell Carcinoma of the Cervix: Treatment and Survival Outcomes of 188 Patients. Am J Obstet Gynecol 2010;203:347.e1-6.
[33] Chen CC, Wang L, Lin JC, Jan JS. The Prognostic Factors for Locally Advanced Cervical Cancer Patients Treated by Intensity-modulated Radiation Therapy with Concurrent Chemotherapy. J Formos Med Assoc 2015;114:231-7.
[34] Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K. Treatment Results and Prognostic Analysis of Radical Radiotherapy for Locally Advanced Cancer of the Uterine Cervix. Br J Radiol 2005;78:821-6.
[35] Ishikawa M, Kasamatsu T, Tsuda H, Fukunaga M, Sakamoto A, Kaku T, et al. A Multi-center Retrospective Study of Neuroendocrine Tumors of the Uterine Cervix: Prognosis According to the New 2018 Staging System, Comparing Outcomes for Different Chemotherapeutic Regimens and Histopathological Subtypes. Gynecol Oncol 2019;155:444-51.
[36] Wang W, Zhou Y, Wang D, Hu K, Zhang F. Prophylactic Extended-field Irradiation in Patients with Cervical Cancer: A Literature Review. Front Oncol 2020;10:579410.
[37] Zivanovic O, Leitao MM Jr., Park KJ, Zhao H, Diaz JP, Konner J, et al. Small Cell Neuroendocrine Carcinoma of the Cervix: Analysis of Outcome, Recurrence Pattern and the Impact of Platinum-based Combination Chemotherapy. Gynecol Oncol 2009;112:590-3.
[38] Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM, Wu HH, et al. Primary Treatment and Prognostic Factors of Small Cell Neuroendocrine Carcinoma of the Uterine Cervix: A Taiwanese Gynecologic Oncology Group Study. Eur J Cancer 2012;48:1484-94.